Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma
Neuro-Oncology · 02.11.2023 · 25 (11) · 2001-2014
DOI: 10.1093/neuonc/noad108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 19.06.2023. Verfasst von Lena Hänsch und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Brain Tumor Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Glioblastoma, Glioma. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swiss National Science Foundation, Clinical Research Priority Program, University of Zurich.
Abstract (Originalsprache)
Background
Chimeric antigen receptor (CAR) T cell therapy has proven to be successful against hematological malignancies. However, exploiting CAR T cells to treat solid tumors is more challenging for various reasons including the lack of suitable target antigens. Here, we identify the transmembrane protein CD317 as a novel target antigen for CAR T cell therapy against glioblastoma, one of the most aggressive solid tumors.
Methods
CD317-targeting CAR T cells were generated by lentivirally transducing human T cells from healthy donors. The anti-glioma activity of CD317-CAR T cells toward various glioma cells was assessed in vitro in cell lysis assays. Subsequently, we determined the efficacy of CD317-CAR T cells to control tumor growth in vivo in clinically relevant mouse glioma models.
Results
We generated CD317-specific CAR T cells and demonstrate strong anti-tumor activity against several glioma cell lines as well as primary patient-derived cells with varying CD317 expression levels in vitro. A CRISPR/Cas9-mediated knockout of CD317 protected glioma cells from CAR T cell lysis, demonstrating the target specificity of the approach. Silencing of CD317 expression in T cells by RNA interference reduced fratricide of engineered T cells and further improved their effector function. Using orthotopic glioma mouse models, we demonstrate the antigen-specific anti-tumor activity of CD317-CAR T cells, which resulted in prolonged survival and cure of a fraction of CAR T cell-treated animals.
Conclusions
These data reveal a promising role of CD317-CAR T cell therapy against glioblastoma, which warrants further evaluation to translate this immunotherapeutic strategy into clinical neuro-oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Brain Tumor Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
- Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
- Division of Antibody-based Immunotherapy, Christian-Albrechts-University, Kiel, Germany.
- Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
- Department of Neurosurgery, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
ORCID-Profile: Matthias Peipp, Maximilian Mastall, Dorothee Gramatzki, Flavio Vasella, Michael Weller, Patrick Roth
Förderung
- Swiss National Science Foundation
- Clinical Research Priority Program
- University of Zurich
- Swiss Cancer Research
- Eurostars-3 programme
Zitieren
APA
Hänsch, L., Peipp, M., Mastall, M., Villars, D., Myburgh, R., Silginer, M., Weiss, T., Gramatzki, D., Vasella, F., Manz, M. G., Weller, M., & Roth, P. (2023). Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma. Neuro-Oncology, 25(11), 2001-2014. https://doi.org/10.1093/neuonc/noad108
Vancouver
Hänsch L, Peipp M, Mastall M, Villars D, Myburgh R, Silginer M, et al. Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma. Neuro-Oncology. 2023;25(11):2001-2014. doi:10.1093/neuonc/noad108
BibTeX
@article{Hnsch2023,
author = {Hänsch, Lena and Peipp, Matthias and Mastall, Maximilian and Villars, Danielle and Myburgh, Renier and Silginer, Manuela and Weiss, Tobias and Gramatzki, Dorothee and Vasella, Flavio and Manz, Markus G and Weller, Michael and Roth, Patrick},
title = {Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma},
journal = {Neuro-Oncology},
year = {2023},
volume = {25},
number = {11},
pages = {2001--2014},
doi = {10.1093/neuonc/noad108}
}
EUVIMED